SCHEMBL7654026

SCHEMBL7654026

CC(=O)On1c(=O)c(-c2cn(CCCN)c3cc(OCc4ccccc4)ccc23)nc2cc3ccccc3cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38
CAMK2D Q13557 4/20 0.37
PPARG P37231 1/20 0.36
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.36
IGF1R P08069 1/20 0.36
MAOB P27338 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
HIF1A Q16665 1/20 0.36
SRD5A2 P31213 1/20 0.35
LTB4R Q15722 1/20 0.35
LTB4R2 Q9NPC1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7658242 0.95 MAOB (0.38) CAMK2DIGF1RMAOBSRD5A2LTB4R
SCHEMBL7851518 0.93 PPARG (0.36) CNR1CNR2PPARGPPARDPPARA
SCHEMBL7663926 0.91 CNR1 (0.37) CNR1CNR2PPARGPPARDPPARA
SCHEMBL7661734 0.91 MAOB (0.38) CNR1CNR2PPARGPPARDPPARA
SCHEMBL8368545 0.91 CAMK2D (0.38) CNR1CNR2CAMK2DPPARGPPARD
SCHEMBL7657833 0.87 MAOB (0.36) IGF1RMAOBSRD5A2LTB4RLTB4R2
SCHEMBL8515918 0.87 IGF1R (0.39) CNR1CNR2CAMK2DPPARGPPARD
SCHEMBL7664668 0.86 MAOB (0.40) PPARGIGF1RMAOBALDH1A1LMNA
SCHEMBL7657954 0.86 MAOB (0.38) PPARGPPARDPPARAIGF1RMAOB
SCHEMBL8362233 0.86 CAMK2D (0.38) CAMK2DIGF1RMAOBSRD5A2LTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6458792-B1 MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. ASTRAZENECA AB (SE) 2002-10-01 US disclosed
EP-1071683-A1 NEW COMPOUNDS AstraZeneca AB (SE) 2001-01-31 EP disclosed
WO-1999046264-A1 NEW COMPOUNDS ASTRAZENECA AB (SE) 1999-09-16 WO disclosed